PortalPublikationenHigh BCAR1 expression is associated with early PSA recurrenc...

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer

Standard

High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. / Heumann, Asmus; Heinemann, Nina; Hube-Magg, Claudia; Lang, Dagmar S; Grupp, Katharina; Kluth, Martina; Minner, Sarah; Möller-Koop, Christina; Graefen, Markus; Heinzer, Hans; Tsourlakis, Maria Christina; Wilczak, Waldemar; Wittmer, Corinna; Jacobsen, Frank; Huland, Hartwig; Simon, Ronald; Schlomm, Thorsten; Sauter, Guido; Steurer, Stefan; Lebok, Patrick; Hinsch, Andrea.

in: BMC CANCER, Jahrgang 18, Nr. 1, 05.01.2018, S. 37.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Heumann, A, Heinemann, N, Hube-Magg, C, Lang, DS, Grupp, K, Kluth, M, Minner, S, Möller-Koop, C, Graefen, M, Heinzer, H, Tsourlakis, MC, Wilczak, W, Wittmer, C, Jacobsen, F, Huland, H, Simon, R, Schlomm, T, Sauter, G, Steurer, S, Lebok, P & Hinsch, A 2018, 'High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer', BMC CANCER, Jg. 18, Nr. 1, S. 37. https://doi.org/10.1186/s12885-017-3956-3

APA

Heumann, A., Heinemann, N., Hube-Magg, C., Lang, D. S., Grupp, K., Kluth, M., Minner, S., Möller-Koop, C., Graefen, M., Heinzer, H., Tsourlakis, M. C., Wilczak, W., Wittmer, C., Jacobsen, F., Huland, H., Simon, R., Schlomm, T., Sauter, G., Steurer, S., ... Hinsch, A. (2018). High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. BMC CANCER, 18(1), 37. https://doi.org/10.1186/s12885-017-3956-3

Vancouver

Heumann A, Heinemann N, Hube-Magg C, Lang DS, Grupp K, Kluth M et al. High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. BMC CANCER. 2018 Jan 5;18(1):37. https://doi.org/10.1186/s12885-017-3956-3

Bibtex

@article{282335eaf5ed44a184e545e0f42af172,
title = "High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer",
abstract = "BACKGROUND: Breast cancer anti-estrogen resistance 1 (BCAR1/p130cas) is a hub for diverse oncogenic signaling cascades and promotes tumor development and progression.METHODS: To understand the effect of BCAR1 in prostate cancer, we analyzed its expression on more than 11,000 prostate cancer samples. BCAR1 expression levels were compared with clinical characteristics, PSA recurrence, molecular subtype defined by ERG status and 3p, 5q, 6q and PTEN deletion.RESULTS: BCAR1 staining was barely detectable in normal prostate glands but seen in 77.6% of 9472 interpretable cancers, including strong expression in 38.5%, moderate in 23.2% and weak in 15.9% of cases. BCAR1 up regulation was associated with positive ERG status (p < 0.0001), high Gleason score (p < 0.0001), advanced pathological tumor stage (p = 0.0082), lower preoperative PSA level (p < 0.0001), increased cell proliferation (p < 0.0001), early PSA recurrence (p = 0.0008), and predicted prognosis independently from clinico-pathological parameters available at the time of the initial biopsy. However, subset analyses revealed that the prognostic impact of BCAR1 expression was limited to ERG-negative cancer. That BCAR1 up regulation was linked to almost all analyzed deletions (p < 0.0001 each for PTEN, 5q, 6q deletion) may suggest a functional link to genomic instability.CONCLUSION: The results of our study identify BCAR1 as a prognostic biomarker with potential clinical value for risk stratification of ERG-negative prostate cancer.",
keywords = "Biomarkers, Tumor, Carcinogenesis, Crk-Associated Substrate Protein, Disease Progression, Estrogens, Gene Expression Regulation, Neoplastic, Humans, Male, Neoplasm Grading, Neoplasm Staging, Prognosis, Prostatic Neoplasms, Journal Article",
author = "Asmus Heumann and Nina Heinemann and Claudia Hube-Magg and Lang, {Dagmar S} and Katharina Grupp and Martina Kluth and Sarah Minner and Christina M{\"o}ller-Koop and Markus Graefen and Hans Heinzer and Tsourlakis, {Maria Christina} and Waldemar Wilczak and Corinna Wittmer and Frank Jacobsen and Hartwig Huland and Ronald Simon and Thorsten Schlomm and Guido Sauter and Stefan Steurer and Patrick Lebok and Andrea Hinsch",
year = "2018",
month = jan,
day = "5",
doi = "10.1186/s12885-017-3956-3",
language = "English",
volume = "18",
pages = "37",
journal = "BMC CANCER",
issn = "1471-2407",
publisher = "BioMed Central Ltd.",
number = "1",

}

RIS

TY - JOUR

T1 - High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer

AU - Heumann, Asmus

AU - Heinemann, Nina

AU - Hube-Magg, Claudia

AU - Lang, Dagmar S

AU - Grupp, Katharina

AU - Kluth, Martina

AU - Minner, Sarah

AU - Möller-Koop, Christina

AU - Graefen, Markus

AU - Heinzer, Hans

AU - Tsourlakis, Maria Christina

AU - Wilczak, Waldemar

AU - Wittmer, Corinna

AU - Jacobsen, Frank

AU - Huland, Hartwig

AU - Simon, Ronald

AU - Schlomm, Thorsten

AU - Sauter, Guido

AU - Steurer, Stefan

AU - Lebok, Patrick

AU - Hinsch, Andrea

PY - 2018/1/5

Y1 - 2018/1/5

N2 - BACKGROUND: Breast cancer anti-estrogen resistance 1 (BCAR1/p130cas) is a hub for diverse oncogenic signaling cascades and promotes tumor development and progression.METHODS: To understand the effect of BCAR1 in prostate cancer, we analyzed its expression on more than 11,000 prostate cancer samples. BCAR1 expression levels were compared with clinical characteristics, PSA recurrence, molecular subtype defined by ERG status and 3p, 5q, 6q and PTEN deletion.RESULTS: BCAR1 staining was barely detectable in normal prostate glands but seen in 77.6% of 9472 interpretable cancers, including strong expression in 38.5%, moderate in 23.2% and weak in 15.9% of cases. BCAR1 up regulation was associated with positive ERG status (p < 0.0001), high Gleason score (p < 0.0001), advanced pathological tumor stage (p = 0.0082), lower preoperative PSA level (p < 0.0001), increased cell proliferation (p < 0.0001), early PSA recurrence (p = 0.0008), and predicted prognosis independently from clinico-pathological parameters available at the time of the initial biopsy. However, subset analyses revealed that the prognostic impact of BCAR1 expression was limited to ERG-negative cancer. That BCAR1 up regulation was linked to almost all analyzed deletions (p < 0.0001 each for PTEN, 5q, 6q deletion) may suggest a functional link to genomic instability.CONCLUSION: The results of our study identify BCAR1 as a prognostic biomarker with potential clinical value for risk stratification of ERG-negative prostate cancer.

AB - BACKGROUND: Breast cancer anti-estrogen resistance 1 (BCAR1/p130cas) is a hub for diverse oncogenic signaling cascades and promotes tumor development and progression.METHODS: To understand the effect of BCAR1 in prostate cancer, we analyzed its expression on more than 11,000 prostate cancer samples. BCAR1 expression levels were compared with clinical characteristics, PSA recurrence, molecular subtype defined by ERG status and 3p, 5q, 6q and PTEN deletion.RESULTS: BCAR1 staining was barely detectable in normal prostate glands but seen in 77.6% of 9472 interpretable cancers, including strong expression in 38.5%, moderate in 23.2% and weak in 15.9% of cases. BCAR1 up regulation was associated with positive ERG status (p < 0.0001), high Gleason score (p < 0.0001), advanced pathological tumor stage (p = 0.0082), lower preoperative PSA level (p < 0.0001), increased cell proliferation (p < 0.0001), early PSA recurrence (p = 0.0008), and predicted prognosis independently from clinico-pathological parameters available at the time of the initial biopsy. However, subset analyses revealed that the prognostic impact of BCAR1 expression was limited to ERG-negative cancer. That BCAR1 up regulation was linked to almost all analyzed deletions (p < 0.0001 each for PTEN, 5q, 6q deletion) may suggest a functional link to genomic instability.CONCLUSION: The results of our study identify BCAR1 as a prognostic biomarker with potential clinical value for risk stratification of ERG-negative prostate cancer.

KW - Biomarkers, Tumor

KW - Carcinogenesis

KW - Crk-Associated Substrate Protein

KW - Disease Progression

KW - Estrogens

KW - Gene Expression Regulation, Neoplastic

KW - Humans

KW - Male

KW - Neoplasm Grading

KW - Neoplasm Staging

KW - Prognosis

KW - Prostatic Neoplasms

KW - Journal Article

U2 - 10.1186/s12885-017-3956-3

DO - 10.1186/s12885-017-3956-3

M3 - SCORING: Journal article

C2 - 29304771

VL - 18

SP - 37

JO - BMC CANCER

JF - BMC CANCER

SN - 1471-2407

IS - 1

ER -